Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06742606
EARLY_PHASE1

Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease

Sponsor: Ain Shams University

View on ClinicalTrials.gov

Summary

Compare efficacy of different biologicals in induction of remission including clinical, laboratory and histopathological remission.

Key Details

Gender

All

Age Range

1 Month - 16 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-01-15

Completion Date

2026-12-13

Last Updated

2024-12-19

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

Group 1 of patients will receive Adalimumab while Group 1 will receive ustekinumab

All the patients will be treated according to guidelines of ECCO/ESPGHAN and will be followed up regularly for 12 months by assessment • response to treatment Frequency of relapses, Regular assessment will be: Clinically every 2 to 4 weeks at gastroenterology outpatient clinic by using activity scoring systems: pediatric Ulcerative Colitis Activity Index pediatric Chron's Disease Activity Index Laboratory follow up will done at weeks 12,24,36,48 of starting or changing to other biological by doing inflammatory markers( CBC, ESR, CRP, albumin. At the end of study(week 48) each patient will be reassessed by: Disease activity: Laboratory Endoscopy will be repeated at week 48 of starting or changing to other biological to assess effect of biologicals on reach mucosal healing.